See II.2.4
The contract concerns a framework agreement for lenalidomide, an oral immunosupressant used mainly therapeutically in myodysplastic syndromes.
See tender documents for the full description of the contract.
Get our periodical newsletter about how sell more to the public sector and how to make the most of Tenderlake.